|
|
|
Volumn 25, Issue 10, 2011, Pages
|
|
FDA approves vemurafenib for treatment of metastatic melanoma
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
B RAF KINASE;
DACARBAZINE;
IPILIMUMAB;
VEMURAFENIB;
ARTHRALGIA;
CANCER CELL;
CANCER GROWTH;
CANCER STAGING;
CANCER SURVIVAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG SAFETY;
DRUG TARGETING;
FATIGUE;
FOOD AND DRUG ADMINISTRATION;
HAIR LOSS;
HUMAN;
MELANOMA;
METASTASIS;
METASTASIS POTENTIAL;
NAUSEA;
NOTE;
OVERALL SURVIVAL;
SIDE EFFECT;
SKIN SENSITIVITY;
SQUAMOUS CELL CARCINOMA;
TREATMENT OUTCOME;
|
|
EID: 80053901141
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
